Saturday, April 24, 2010
Monday, April 19, 2010
BOSTON, April 13 (Reuters) - Orexigen Therapeutics Inc (OREX.O) said on Tuesday that fewer patients achieved key weight loss goals when taking its experimental obesity drug than originally reported, sending the company's stock down 11 percent.
The company said only 50.5 percent of patients who took the drug, Contrave, lost 5 percent or more of their body weight after 56 weeks, compared with a previously reported figure of 56.3 percent.
For more information: Click here to visit Will Clower's website.